☆ 4.3 Article

Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease

SMALL SCIENCE (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease

Wei-Chung Chiou et al.

Summary: The COVID-19 pandemic has caused a global health crisis, and developing effective treatments is crucial. This study investigates the role of SARS-CoV-2 3CLpro in viral replication and identifies natural compounds PGG and EGCG as potential inhibitors. The findings highlight the therapeutic potentials of PGG and EGCG for treating SARS-CoV-2 infection.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Add to Collection

Article Infectious Diseases

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Katherine A. Twohig et al.

Summary: A study in England found that patients with COVID-19 infected with the delta variant were more likely to be admitted to hospital or attend emergency care compared to those infected with the alpha variant. This suggests that outbreaks of the delta variant in unvaccinated populations may pose a greater burden on healthcare services.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging

Wioletta Rut et al.

Summary: A team of researchers synthesized a new type of antiviral agent, demonstrating through experiments its high efficacy in inhibiting SARS-CoV-2 with a low effective concentration, providing new insights for antiviral treatment. By observing the active SARS-CoV-2 M-pro in the cells of patients infected with COVID-19, important clues were provided for the design of antiviral drugs and diagnostic tests.

NATURE CHEMICAL BIOLOGY (2021)

Add to Collection

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Potential SARS-CoV-2 main protease inhibitors

Riddhidev Banerjee et al.

Summary: This review focuses on recent developments in the search for small-molecule inhibitors targeting the SARS-CoV-2 M-pro, aiming at discovering and designing drugs targeting the key target in the viral replication cycle.

DRUG DISCOVERY TODAY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Potential inhibitors of SARS-CoV-2: recent advances

Ghazaleh Jamalipour Soufi et al.

Summary: The emergence of SARS-CoV-2 in 2019 has led to the global pandemic of COVID-19, prompting a desperate search for vaccines and treatments. Current research focuses on targeting virus-host interactions and interfering with viral replication signaling pathways. There is an urgent need for safe and broad-spectrum antiviral agents and strategies against SARS-CoV-2.

JOURNAL OF DRUG TARGETING (2021)

Add to Collection

Review Chemistry, Medicinal

What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design

Muya Xiong et al.

Summary: The emergence of various coronaviruses in recent decades has posed significant threats to global health, with the ongoing COVID-19 pandemic causing millions of infections and deaths worldwide. The 3C-like protease (3CL(pro)) is seen as a promising target for antiviral intervention due to its essential role in viral replication and its conserved structural features among different coronaviruses. Research focusing on the crystal structures of 3CL(pro) and their inhibitors aims to provide insights into inhibition mechanisms and guide future drug discovery efforts.

MEDICINAL RESEARCH REVIEWS (2021)

Add to Collection

Article Virology

Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2

Shiling Hu et al.

Summary: The study revealed that salvianolic acids A, B, and C from Salvia miltiorrhiza can inhibit the entry of 2019-nCoV pseudovirus into ACE2(h) cells by binding to the RBD of the 2019-nCoV spike protein and ACE2 protein.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry

Dingqi Zhang et al.

Summary: The study identified natural compounds like EGCG and Bkc as potential SARS-CoV-2 entry inhibitors, showing effectiveness in inhibiting viral entry into cells and potential antiviral activity, opening up possibilities for further research and development.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

Shin-ichiro Hattori et al.

Summary: In this study, two small-molecule compounds, GRL-1720 and 5h, are characterized for their anti-SARS-CoV-2 properties targeting the virus main protease (M-pro). These compounds showed synergistic antiviral effects when combined with remdesivir in vitro, indicating their potential as lead inhibitors for the development of therapeutics against SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

Sebastian Guenther et al.

Summary: The study identified 37 compounds that bind to the SARS-CoV-2 main protease through a high-throughput x-ray crystallographic screen of two repurposing drug libraries. Among these compounds, one peptidomimetic and six nonpeptidic compounds showed antiviral activity in cell-based viral reduction assays at nontoxic concentrations. The identification of two allosteric binding sites presents potential targets for drug development against SARS-CoV-2.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease

Haixia Su et al.

Summary: The naturally occurring flavonoid myricetin is identified as a non-peptidomimetic and covalent inhibitor of SARS-CoV-2 3CL protease. Crystal structures reveal the pyrogallol group modifies the catalytic cysteine through covalent binding. This study provides insights into the mechanism of action of pyrogallol-containing natural products and offers a template for designing non-peptidomimetic covalent inhibitors against 3CL proteases.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

Jinbiao Liu et al.

Summary: The study demonstrated that green tea beverage or its major ingredient, epigallocatechin gallate (EGCG), were highly effective in inhibiting live SARS-CoV-2 and human coronavirus infection, especially against new variants. Among the 4 active green tea catechins, EGCG showed the strongest antiviral effect by interfering with the binding of viral spikes to host cell receptors.

CELL AND BIOSCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Wenhao Dai et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Zhenming Jin et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

Zhenming Jin et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics

Qingke Li et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells

Ekaterina V. Vinogradova et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Lifeng Fu et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Alice Douangamath et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site

Jaeyong Lee et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Immunology

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

Mei-Yue Wang et al.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)

Add to Collection

Review Chemistry, Medicinal

Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities

Weiyan Cheng et al.

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)

Add to Collection

Review Chemistry, Multidisciplinary

Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics

Zhuo-ming Li et al.

ACTA PHARMACOLOGICA SINICA (2018)

Add to Collection

Article Multidisciplinary Sciences

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

Hongbin He et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Review Food Science & Technology

Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review

Ren-You Gan et al.

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2018)

Add to Collection

Article Plant Sciences

Demystifying traditional herbal medicine with modern approaches

Fu-Shuang Li et al.

NATURE PLANTS (2017)

Add to Collection

Article Pharmacology & Pharmacy

Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions

R. Scott Obach et al.

DRUG METABOLISM AND DISPOSITION (2007)

Add to Collection

Article Biochemistry & Molecular Biology

Design of wide-spectrum inhibitors targeting coronavirus main proteases

HT Yang et al.

PLOS BIOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.